Overview

Multiple Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes

Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
BMS-820132 is an investigational new drug being developed by BMS for treating Type 2 diabetes. The purpose of this study is to test the safety/tolerability (potential side effects) of multiple doses of the investigational new drug, as well as the amount of study drug in the blood and its effects on blood sugar,in subjects with type 2 diabetes.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb